Pirbuterol is a beta-2 adrenergic agonist and bronchodilator used for the symptomatic treatment of asthma. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol.
- Mechanism
- Curator reviewed
The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3†,5†-adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
- Primary indication
- For the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible bronchospasm including asthma.Curator reviewed
- Formula / weight
- C12H20N2O3 · 240.2988 g/mol (avg)
- First approval
- Canada, 1996 · United States, 1992
- Also known as
- (+/-)-pirbuterol
- Code names
- ARA-211
Resolves to
VQDBNKDJNJQRDG-UHFFFAOYSA-NSMILESCC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1What you can answer from here — as of September 13, 2026
Which drugs share a target with Pirbuterol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account